Crinetics Pharmaceuticals, Inc. — Director's Dealing 2020

Feb 11, 2020

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2019-12-31

Reporting Person: Struthers Richard Scott (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-08-13	Common Stock	G	300000	$0.00	Disposed	925805	Indirect
2019-08-13	Common Stock	G	100000	$0.00	Acquired	100000	Indirect
2019-08-13	Common Stock	G	100000	$0.00	Acquired	100000	Indirect
2019-08-13	Common Stock	G	100000	$0.00	Acquired	100000	Indirect